首页> 外文期刊>The journal of Tehran Heart Center. >Clinical, Laboratory, and Procedural Predictors of No-Reflow in Patients Undergoing Primary Percutaneous Coronary Intervention
【24h】

Clinical, Laboratory, and Procedural Predictors of No-Reflow in Patients Undergoing Primary Percutaneous Coronary Intervention

机译:在经皮冠状动脉介入的患者中无回流的临床,实验室和程序预测因子

获取原文
           

摘要

Background: No-reflow is a major challenging issue in the management of patients with ST-segment elevation myocardial infarction (STEMI) undergoing primary percutaneous coronary intervention (PPCI). This study aimed to investigate the clinical, laboratory, and procedural predictors of no-reflow. Methods: This study was conducted on 378 patients with STEMI admitted to Dr. Heshmat Educational and Remedial Center (a referral heart hospital in Rasht, Iran) between 2015 and 2017. The study population was divided based on the thrombolysis in myocardial infarction (TIMI) flow grade and the myocardial blush grade into no-reflow and reflow groups. The clinical, laboratory, and procedural characteristics at admission were compared between the 2 groups using the multivariate logistic regression analysis. Results: The mean age of the participants was 58.57±11.49 years, and men comprised 74.1% of the study population. The no-reflow phenomenon was found in 77 patients. The no-reflow group was significantly older and more likely to be female; additionally, it had higher frequencies of hypertension, diabetes mellitus, hyperlipidemia, and a history of cardiovascular diseases. The multivariate logistic regression analysis showed that age 60 years (OR=1.05, 95% CI:1.00–1.09), hypertension (OR=2.91, 95% CI:1.35–6.27), diabetes (OR=4.18, 95% CI:1.89–9.22), a low systolic blood pressure (OR=3.53, 95% CI:1.02–12.2), a history of cardiovascular diseases (OR=4.29, 95% CI:1.88–9.77), chronic heart failure (OR=4.96, 95% CI:1.23–20), a low initial TIMI flow grade (OR=7.58, 95% CI:1.46–39.2 ), anemia (OR=3.42, 95% CI:1.33–8.77), and stenting vs. balloon angioplasty (OR=0.42, 95% CI:0.19–0.91) were the significant independent predictors of no-reflow. Conclusion: This study revealed some clinical, laboratory, and procedural predictors of no-reflow for the prediction of high-risk patients and their appropriate management to reduce the risk of no-reflow.
机译:背景:No-Restrov是在初前经皮冠状动脉介入(PPCI)的患者中管理患者中的一个主要挑战性问题。本研究旨在调查无回流的临床,实验室和程序预测因子。方法:本研究于2015年至2015年间录取了378名STEMI的患者患有Heshmat教育和补救中心(Rasht,伊朗的Rausht Carrecture医院)。该研究人口基于心肌梗死(Timi)的溶栓分析流量等级和心肌腮红等级进入无回流和回流组。使用多元逻辑回归分析比较2组之间的临床,实验室和程序特征。结果:参与者的平均年龄为58.57±11.49岁,男性组成74.1%的研究人口。在77名患者中发现了无回流现象。 No-Respro Rover Group明显老了,更有可能是女性;此外,它具有较高的高血压频率,糖尿病,高脂血症和心血管疾病的历史。多变量逻辑回归分析显示,年龄> 60岁(或= 1.05,95%CI:1.00-1.09),高血压(或= 2.91,95%CI:1.35-6.27),糖尿病(或= 4.18,95%CI: 1.89-9.22),低收缩压(或= 3.53,95%CI:1.02-12.2),心血管疾病的历史(或= 4.29,95%CI:1.88-9.77),慢性心力衰竭(或= 4.96 ,95%CI:1.23-20),初始初始流量等级(OR = 7.58,95%CI:1.46-39.2),贫血(或= 3.42,95%CI:1.33-8.77)和抵销与气球血管成形术(或= 0.42,95%CI:0.19-0.91)是无回流的重要独立预测因子。结论:本研究揭示了一些临床,实验室和无回流的程序预测因子,用于预测高风险患者及其适当的管理,以降低无回流风险。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号